ANI Pharmaceuticals Statistics
Share Statistics
ANI Pharmaceuticals has 21.65M
shares outstanding. The number of shares has increased by 3.82%
in one year.
| Shares Outstanding | 21.65M |
| Shares Change (YoY) | 3.82% |
| Shares Change (QoQ) | 3.54% |
| Owned by Institutions (%) | 99.35% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 47 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 1.86M, so 8.6% of the outstanding
shares have been sold short.
| Short Interest | 1.86M |
| Short % of Shares Out | 8.6% |
| Short % of Float | 10.81% |
| Short Ratio (days to cover) | 3.41 |
Valuation Ratios
The PE ratio is -57.66 and the forward
PE ratio is 8.23.
ANI Pharmaceuticals's PEG ratio is
0.3.
| PE Ratio | -57.66 |
| Forward PE | 8.23 |
| PS Ratio | 1.74 |
| Forward PS | 1.3 |
| PB Ratio | 2.49 |
| P/FCF Ratio | 22.69 |
| PEG Ratio | 0.3 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for ANI Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.72,
with a Debt / Equity ratio of 1.46.
| Current Ratio | 2.72 |
| Quick Ratio | 2.02 |
| Debt / Equity | 1.46 |
| Debt / EBITDA | 7.89 |
| Debt / FCF | 13.26 |
| Interest Coverage | 0.03 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $684,923.08 |
| Profits Per Employee | $-20,648.83 |
| Employee Count | 897 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 1.83 |
Taxes
| Income Tax | -3.69M |
| Effective Tax Rate | 16.61% |
Stock Price Statistics
The stock price has increased by -9.4% in the
last 52 weeks. The beta is 0.56, so ANI Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.56 |
| 52-Week Price Change | -9.4% |
| 50-Day Moving Average | 65.89 |
| 200-Day Moving Average | 60.31 |
| Relative Strength Index (RSI) | 35.3 |
| Average Volume (20 Days) | 406,417 |
Income Statement
In the last 12 months, ANI Pharmaceuticals had revenue of 614.38M
and earned -18.52M
in profits. Earnings per share was -0.87.
| Revenue | 614.38M |
| Gross Profit | 364.17M |
| Operating Income | 584K |
| Net Income | -18.52M |
| EBITDA | 79.15M |
| EBIT | -4.61M |
| Earnings Per Share (EPS) | -0.87 |
Full Income StatementBalance Sheet
The company has 144.86M in cash and 624.09M in
debt, giving a net cash position of -479.23M.
| Cash & Cash Equivalents | 144.86M |
| Total Debt | 624.09M |
| Net Cash | -479.23M |
| Retained Earnings | -100.28M |
| Total Assets | 1.29B |
| Working Capital | 334.48M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 64.02M
and capital expenditures -16.95M, giving a free cash flow of 47.06M.
| Operating Cash Flow | 64.02M |
| Capital Expenditures | -16.95M |
| Free Cash Flow | 47.06M |
| FCF Per Share | 2.44 |
Full Cash Flow StatementMargins
Gross margin is 59.27%, with operating and profit margins of 0.1% and -3.01%.
| Gross Margin | 59.27% |
| Operating Margin | 0.1% |
| Pretax Margin | -3.62% |
| Profit Margin | -3.01% |
| EBITDA Margin | 12.88% |
| EBIT Margin | 0.1% |
| FCF Margin | 7.66% |
